|
|
|
| 雄激素剥夺联合阿帕他胺治疗转移性激素敏感性前列腺癌2例报道 |
| 杜仁继, 缪惠东* |
| 苏州大学附属张家港医院泌尿外科 ,张家港 215600 |
|
| Androgen deprivation therapy combined with apalutamide in the treatment of metastatic hormone-sensitive prostate cancer: report of 2 cases |
| Du Renji, Miao Huidong* |
| Department of Urology, Affiliated Zhangjiagang Hospital of Suzhou University, Zhangjiagang 215600 |
[1] 付振涛,郭晓雷,张思维,等. 2015年中国前列腺癌发病与死亡分析[J]. 中华肿瘤杂志,2020,42(9):718-722.
[2] CATTRINI C, CASTRO E, LOZANO R, et al.Current treatment options for metastatic hormone-sensitive prostate Cancer[J]. Cancers (Basel), 2019, 11(9):1355.
[3] 中华医学会泌尿外科学分会,中国前列腺癌联盟. 转移性前列腺癌化疗中国专家共识(2019版)[J]. 中华泌尿外科杂志,2019,40(10):721-725.
[4] CORNFORD P, VANDEN BERGH RCN, BRIERS E, et al.EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part Ⅱ-2020 update: treatment of relapsing and metastatic prostate Cancer[J]. Eur Urol, 2021,79(2):263-282.
[5] CLEGG NJ, WONGVIPAT J, JOSEPH JD, et al.ARN-509: a novel antiandrogen for prostate cancer treatment[J]. Cancer Res, 2012, 72(6):1494-1503.
[6] RATHKOPF DE, SCHER HI.Apalutamide for the treatment of prostate cancer[J]. Expert Rev Anticancer Ther, 2018, 18(9):823-836.
[7] SATO H, NARITA S, TSUCHIYA N, et al.Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer[J]. BMC Urol, 2018, 18(1):32
[8] FURUYA Y, NAGAKAWA O, FUSE H.Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer[J]. Urol Int, 2003, 70(3):195-199.
[9] AFRIANSYAHf A, HAMID ARAH, MOCHTAR CA, et al.Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis[J]. F1000Res, 2018, 7:246.
[10] KYRIAKOPOULOS CE, CHEN YH, CARDUCCI MA, et al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase Ⅲ E3805 CHAARTED Trial[J]. J Clin Oncol, 2018,36(11):1080-1087.
[11] SCHER HI, BEER TM, HIGANO CS, et al.Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study[J]. Lancet, 2010, 375(9724):1437-1446.
[12] RYDZEWSKA LHM, BURDETT S, VALE CL, et al.Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis[J]. Eur J Cancer, 2017,84:88-101.
[13] CHI KN, AGARWAL N, BJARTELL A, et al.Apalutamide for metastatic, castration-sensitive prostate cancer[J]. N Engl J Med, 2019, 381(1):13-24. |
| [1] |
叶剑钧, 鲍一歌, 沈朋飞, 刘振华, 杨璐, 张朋, 李响, 曾浩, 魏强. 阿帕他胺治疗晚期前列腺癌32例报道[J]. 微创泌尿外科杂志, 2022, 11(2): 76-80. |
| [2] |
陈亮, 吴天鹏, 宋超, 刘凌琪, 禹刚. 阿帕他胺治疗高龄转移性激素敏感性前列腺癌2例报道并文献复习[J]. 微创泌尿外科杂志, 2022, 11(2): 123-127. |
| [3] |
卢凯, 陈恕求, 吴剑平, 许斌, 陈明. 以血小板减少为首发症状的前列腺癌骨髓转移1例报道[J]. 微创泌尿外科杂志, 2022, 11(2): 131-133. |
| [4] |
路义, 王鹏, 赵海军, 邓军, 张晏, 吴帅, 祝海. 局部进展期前列腺癌综合诊疗1例并文献复习[J]. 微创泌尿外科杂志, 2022, 11(2): 128-130. |
| [5] |
张培新 贾宏亮 艾尼娃 蒲春林 陈建森 文彬 李鸣 李赟. 经会阴及经直肠前列腺穿刺活检安全性比较分析[J]. 微创泌尿外科杂志, 2016, 5(5): 281-284. |
| [6] |
成建军,柯鑫文,张华俊,程伟,尚吉文,米振国,张雁钢. 前列腺平滑肌肉瘤1例报告并文献复习[J]. 微创泌尿外科杂志, 2015, 4(1): 48-50. |
| [7] |
张帆, 黄毅, 陆敏, 马潞林. 临床低危型前列腺癌根治性切除术后病理升级的危险因素分析[J]. 微创泌尿外科杂志, 2013, 2(4): 280-283. |
|
|
|
|
